BD Invests $100 Million in Nebraska Plant to Expand Insulin Syringe Manufacturing

22 Sep 2016

Awards and Recognition

FRANKLIN LAKES, N.J., Sept. 22, 2016 – BD (Becton, Dickinson and Company)
(NYSE: BDX), a leading global medical technology company, today announced it is
investing $100 million in its Holdrege, Neb. facility to expand capacity for its insulin
syringe manufacturing operations.

The investment will be used for new technology and manufacturing equipment to
expand capacity for BD insulin syringes. BD already produces more than 2 billion
insulin syringes each year, which averages to be more than 250,000 syringes per

“About 40 percent of people with diabetes who inject insulin use syringes as part of
their diabetes management regimen,” said Ken Miller, worldwide president of
Diabetes Care for BD. “This investment will provide benefits to this diabetes
population and underscores our commitment to supply high-quality, industryleading
insulin syringes to patients.”

BD began operations in Holdrege in 1966 in a 12,000 square foot building with 66
associates. Today, the facility has grown to 350,000 square feet with more than
650 associates manufacturing 20 different BD products. BD is the largest employer
in Phelps County. Across Nebraska, BD employs more than 2,500 associates in four
manufacturing facilities in Holdrege, Broken Bow and two in Columbus.

About BD
BD is a global medical technology company that is advancing the world of health by
improving medical discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that enable medical
research and clinical laboratories. The company provides innovative solutions that
help advance medical research and genomics, enhance the diagnosis of infectious
disease and cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, optimize respiratory care
and support the management of diabetes. The company partners with organizations
around the world to address some of the most challenging global health issues. BD
has more than 45,000 associates across 50 countries who work in close
collaboration with customers and partners to help enhance outcomes, lower health
care delivery costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit